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and Harald Ehrhardt1,4*Abstract
Background: The p53 protein is the best studied target in human cancer. For decades, p53 has been believed to
act mainly as a tumor suppressor and by transcriptional regulation. Only recently, the complex and diverse function
of p53 has attracted more attention. Using several molecular approaches, we studied the impact of different p53
variants on extrinsic and intrinsic apoptosis signaling.
Results: We reproduced the previously published results within intrinsic apoptosis induction: while wild-type p53
promoted cell death, different p53 mutations reduced apoptosis sensitivity. The prediction of the impact of the p53
status on the extrinsic cell death induction was much more complex. The presence of p53 in tumor cell lines and
primary xenograft tumor cells resulted in either augmented, unchanged or reduced cell death. The substitution of
wild-type p53 by mutant p53 did not affect the extrinsic apoptosis inducing capacity.
Conclusions: In summary, we have identified a non-expected impact of p53 on extrinsic cell death induction. We
suggest that the impact of the p53 status of tumor cells on extrinsic apoptosis signaling should be studied in detail
especially in the context of therapeutic approaches that aim to restore p53 function to facilitate cell death via the
extrinsic apoptosis pathway.
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The known functions of p53 are becoming increasingly
complex and involvement of p53 in transcriptional con-
trol impacts many cellular functions including cell death
control, cell cycle arrest, cellular senescence, DNA re-
pair, angiogenesis, cell migration and other fundamental
physiologic cellular activities including cell metabolism,
autophagy, stem cell renewal, embryogenesis, innate im-
munity and fertility [1]. The prediction of the precise ac-
tion of p53 on a specific cell and within a special
context remains the focus of research activities and the
impact on transcriptional control and the cell cycle is
strictly context-specific [2-7]. p53 is classically viewed
for its transcriptional control of pro-apoptotic proteins* Correspondence: Harald.Ehrhardt@helmholtz-muenchen.de
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reproduction in any medium, provided the orlike DR5, Caspase-8, Bax, PUMA or NOXA, and its ac-
cumulation and activation is regulated by transcription
and by a panel of post-transcriptional modifications like
phosphorylation, subcellular localization and interaction
with negative regulators [1].
Targeted therapies that specifically modulate a specific
step of cell death induction in tumor cells represent one
of the main goals of ongoing preclinical and clinical
studies to improve cancer therapy. For p53, the selective
modulation of mutant p53 and the variation of p53 ex-
pression levels by direct or indirect stabilization repre-
sent the most promising approaches within current
studies [8,9]. In contrast to the many ongoing studies
using mostly biochemical modulations, the specific im-
pact of p53 gene alterations was investigated in a limited
number of studies with respect to the general impact on
intrinsic cell death induction [5,7,10-12]. Within the re-
search activities of the extrinsic cell death induction by
death inducing ligands like TRAIL, the focus was ex-
clusively drawn to the promising approaches of p53l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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motherapeutic drugs or targeted stimuli [3,4,13].
In the study presented here, the specific impact of the
altered p53 status on extrinsic and intrinsic apoptosis in-
duction was studied in detail. We used different molecu-
lar approaches as has been done i.e. for tumorigenesis in
different p53 genetic backgrounds before [14,15].
Results
Restoration of p53 functionality and activation of p53 to
improve the efficacy of tumor therapy have attracted much
attention within many different tumor entities and have
demonstrated superior cell death induction for many com-
binations [3,13,16]. In contrast, the presence or activation
of p53 within certain therapeutic settings was shown to be
of disadvantage for the therapy efficacy in vitro and in vivo
[2,17]. Here we aimed to study the impact of the p53 status
itself on extrinsic and intrinsic apoptosis sensitivity.
Generation of constructs to modulate the p53 status
To study the impact of p53 on extrinsic and intrinsic
apoptosis induction after defined stimuli, we used three
different approaches: I) expression of p53 in wild-type or
mutant conformation in tumor cells. II) knockdown of
p53 by RNA interference. III) the use of pairs of tumor
cells with baseline p53 expression and with the somatic
knock-out of p53. For the first experimental setting, we
generated p-CDH constructs either containing p53 in wild-
type conformation or with specific point mutations for
lentiviral transduction. The FKBP destabilization domain
tagged to overexpressed p53 conducts the proteasomal
degradation. Transient expression of the transgene was
achieved after adding SHIELD-1.
Constructs were expressed in different tumor cells either
with somatic knockout of p53 (Figures 1 and 2), loss of
p53 (Additional file 1: Figure S3C) or with expression of
wild-type p53 (Additional file 1: Figure S2). Five different
mutant forms of p53 were introduced by mutagenesis
which are known to be associated with reduced protein
stability (V143A), defect of DNA binding (R248W,
R273H) or structural instability (R175H, R249S) (Figure 2
and Additional file 1: Figure S2) [16]. For the second ap-
proach, the previously described technique of RNA inter-
ference against p53 using a lentiviral system was used
[2-4] to generate an efficient knockdown of p53 (Figure 3A
and Additional file 1: Figure S3). For the last approach, ac-
cess to pairs of tumor cells either expressing p53 or with
somatic knock-out of p53 was obtained (Figures 1, 2 and
3A, Additional file 1: Figure S3B).
Impact of p53 on extrinsic apoptosis sensitivity in
HCT116 cells
First we used HCT116 cells either expressing p53 in
wild-type conformation or with somatic knock-out ofp53. Additionally p53 in wild-type conformation was re-
introduced in the p53-/- cells. To our surprise, cell death
induction by the death inducing ligand TRAIL was aug-
mented in the absence of p53 (Figure 1A). The increased
apoptosis sensitivity was not attributable to any regulation
of apoptosis signaling proteins involved in TRAIL signal-
ing. On the receptor level, the p53 status did not impact
DR4 and DR5 expression levels (Figure 1B). In an alterna-
tive approach, cells were transfected with the TRAIL death
receptors DR4 and DR5, and overexpression did not
impact apoptosis induction by TRAIL (Additional file 1:
Figure S1). Downstream of the TRAIL death receptors,
the p53 status did not change the expression levels of the
further members of the DISC and of the most important
members of the Bcl-2 and the IAP-family (Figure 1C). Be-
yond transcriptional control, neither the cell cycle distri-
bution nor the spontaneous growth was affected by the
p53 status (Figure 1D and E).
Different impact of mutant p53 on extrinsic and intrinsic
cell death induction
Next we studied the impact of wild-type and mutant p53
on extrinsic and intrinsic cell death induction in the
HCT116 cells. As published before, wild-type p53 sig-
nificantly augmented the cell death induction by doxo-
rubicin, while the five studied p53 mutants did not affect
the apoptosis inducing capacity (Figure 2A). Comparable
results were obtained when doxorubicin was substituted
by 5-fluorouracil, another cytotoxic drug acting by DNA
damage and activation of the intrinsic apoptosis signal-
ing cascade (data not shown) [18].
When TRAIL was studied as a classical activator of
the extrinsic apoptosis signaling cascade, the impact of
mutant p53 was completely different. The five different
mutants of p53 reduced the TRAIL sensitivity to a similar
extent as p53 in wild-type conformation further arguing
against transcriptional control as the central regulatory
mechanism of action (Figure 2B) [5,6]. When SHEP cells,
which express p53 in wild-type conformation where
overexpressed with wild-type p53 or the five different mu-
tant forms of p53, the identical results were obtained as in
HCT116 cells. While the sensitivity for doxorubicin or 5-
fluorouracil was augmented when wild-type p53 was
overexpressed (Additional file 1: Figure S2A and data not
shown), wild-type p53 overexpression reduced the sensitiv-
ity for extrinsic apoptosis induction. As observed in
HCT116 cells, not the p53 status but the overexpression
of p53 was associated with reduced TRAIL sensitivity
(Additional file 1: Figure S2B). Similar results were
obtained, when the extrinsic signaling cascade was stimu-
lated with the death inducing ligand FasL (data not shown).
Taken together, we have identified a distinct regulation
of extrinsic and intrinsic cell death by p53. While the
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Figure 1 (See legend on next page.)
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Figure 1 Impact of p53 on extrinsic apoptosis sensitivity in HCT116 cells. A) HCT116 p53+/+, untransfected HCT116 p53-/- cells (co) and
HCT116 p53-/- cells transfected with pCDH p53 in wild-type conformation (p53 wt) were stimulated with TRAIL (100 ng/ml) for 48 hours.
Measurements of cell death induction (left panel) and cleavage of Bid and Caspase-3 (Casp-3; right panel) are presented. Western blot analysis
was performed of total cellular protein. For the ease of reading, the order of samples within the identical blot was rearranged without any further
manipulation, indicated by the separating lines. cl = cleaved. B, C) Cells from Figure 1A were analyzed for TRAIL death receptor (B) and apoptosis
signaling protein (C) expression. DR4 and DR5 expression was determined by FACs surface staining. The MFI (mean fluorescence intensity) was
determined in the APC-Cy7 channel of a LSR II flow cytometer as described in Methods. cl. Bid = cleaved Bid. D, E) Cells from Figure 1A were
analyzed for cell cycle distribution using propidium iodide staining (D) and for spontaneous growth by automated analyses of the well area
covered over time (E). Cell death induction of adherent cells was measured by Nicoletti staining. Specific apoptosis was calculated as [(apoptosis
of stimulated cells at end point minus apoptosis of unstimulated cells at end point) divided by (100 minus apoptosis of unstimulated cells at end
point) times 100]. Statistical analysis was performed using one way RM ANOVA. *p < 0,05, NS = statistically not significant.
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ated with reduced extrinsic cell death induction in
HCT116 and SHEP cells. Unexpectedly and in contrast to
intrinsic apoptosis signaling, wild-type and mutant p53
had the identical impact on extrinsic apoptosis induction.
The heterogenous impact of p53 on extrinsic cell death
induction in tumor cell lines
To further clarify the role of p53 for extrinsic cell death,
we studied n = 12 pairs of tumor cell lines expressing
p53 and with downregulation / knock-out of p53. Over-
all, we observed three different phenotypes that were asso-
ciated with the presence of p53: reduced, unchanged or
augmented sensitivity for extrinsic cell death induction by
TRAIL (Figure 3A and Additional file 1: Figure S3).
Surprisingly, the inhibition or loss of p53 was associated
with reduced TRAIL sensitivity in only 2 / 12 cell lines
tested, while in 5 / 12 it did not have any impact and in 5
/ 12 was associated with augmented cell death induction
by TRAIL (Figure 3B). The negative action of p53 on
TRAIL sensitivity was observed in hematopoietic, solid
and mesenchymal tumor cells. Furthermore, the TRAIL
response was independent from the TRAIL sensitivity of
the parental cells and inhibition of apoptosis induction by
TRAIL was detected in tumor cell lines with wildtype and
mutant p53 status (Figure 3C) [16]. In line, the baseline
p53 expression level varied widely between the different
cell lines without any specific pattern (Figure 3D).
In summary, the impact of p53 on extrinsic cell death
induction is much more complex and different actions
were observed depending on the individual tumor cell
which did not fit in classical categories like tumor entity,
drug sensitivity or p53 mutation status of the tumor cell.
The heterogenous impact of p53 on extrinsic cell death
induction in xenografted ALL cells
As the inhibitory effect on TRAIL sensitivity was present
in nearly half of the tumor cell lines with wildtype p53 sta-
tus, we chose the ALL xenograft setting to further study
the relevance of wildtype p53 for inhibition of extrinsiccell death as they rarely contain p53 mutations [19,20].
We confirmed the wildtype p53 status in all ALL xeno-
graft samples presented (data not shown). Another ad-
vantage of the employed experimental setting is that
xenograft cells better resemble the in vivo situation as
they do not feature non-physiologic alterations or com-
prise a selection of mutations that do not resemble the
patient situation. We studied the impact of p53 on
TRAIL sensitivity in xenografted ALL cells using the re-
cently described experimental setting of RNA interfer-
ence after amplification of primary childhood ALL cells
in NOD/SCID mice [3,4,7,21-24]. RNA interference
against p53 markedly reduced the p53 expression as de-
scribed before (Additional file 1: Figure S4 and data not
shown) [21]. As identified for the cell lines studies in
Figure 3, xenografted ALL cells with knockdown of p53
reacted with three different phenotypes after stimulation
with TRAIL: reduced, unchanged or augmented cell
death induction (Figure 4A and data not shown). Surpris-
ingly, the distribution of actions of p53 on extrinsic cell
death was nearly identical as in the cell lines (Figure 4B).
The negative effect of p53 on TRAIL sensitivity was
present in B- and T-ALL cells and was detected only in
samples obtained at initial diagnosis although the small
number of samples at relapse studied does not allow the
conclusion that in the situation of relapse the impact of p53
on extrinsic signaling is always not negative. When samples
were categorized for their TRAIL response the same obser-
vation as in cell lines was detected: the fraction of samples
benefiting from the knockdown of p53 was higher in the
group of TRAIL resistant samples (Figure 4C). In contrast to
the cell line data, the baseline p53 expression level between
the different xenograft samples was less inhomogenous
and showed a similar distribution for the three categories
of the observed TRAIL responses (Figure 4D).
Taken together, the data obtained in established cell
lines were confirmed in patient-derived tumor cells and
underline the clinical relevance of the described pheno-
type: heterogeneous impact of p53 on extrinsic cell death
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Figure 2 Different impact of mutant p53 on extrinsic and
intrinsic cell death induction in HCT116 cells. A,B) HCT116
p53-/- cells transfected with the different pCDH constructs
containing wildtype p53 or p53 with point mutation at codon 143,
175, 248, 249 or 273 were stimulated with doxorubicin (100 ng/ml,
72 hours, A) or TRAIL (100 ng/ml, 48 hours, B). Cell death induction,
calculation of specific apoptosis, presentation of data and Western
Blot analysis were performed as in Figure 1. Statistical analysis was
performed using one way RM ANOVA. *p < 0,05, NS = statistically
not significant.
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The data presented here indicate that both overexpression
of wild-type or mutant p53 in cancer cells can have nega-
tive effects on cell death induction via the extrinsic apop-
tosis signaling cascade. These findings need to be taken
into consideration during designing therapeutic strategies
intended to re-introduce p53. While we were able to re-
produce the formerly described heterogeneous impact of
wild-type and mutant p53 on apoptosis induction bycytotoxic drugs like doxorubicin that act via the intrinsic
signaling cascade [10,11], the impact of the p53 status on
the extrinsic apoptosis cascade activated by death inducing
ligands like TRAIL is much more complex. Investigating a
panel of tumor cell lines and xenografted primary tumor
cells, we detected three different actions of p53 on extrin-
sic apoptosis induction and the distribution of the three
phenotypes was nearly equal between cell lines and xeno-
graft cells: Promotion of extrinsic apoptosis induction, no
change of apoptosis sensitivity and inhibition of cell death
in the presence of p53. Surprisingly, the presence of p53
either in wild-type or mutant conformation did not signi-
ficantly impact the expression level of typically p53-
regulated apoptosis proteins like Bax, PUMA or DR5,
spontaneous growth or cell cycle distribution [13]. While
the impact of p53 on extrinsic apoptosis signaling was so
far exclusively / mainly studied for the situation of p53
activation, the data provided here clearly indicate that the
p53 status of the tumor cells impacts the response to ex-
trinsic apoptosis stimuli while classical targets of p53 ac-
cumulation are not affected. Using RNA interference for
p53 knockdown, somatic knockout of p53 and p53 re-
expression strategies, the impact of basal p53 expression
was studied in detail. Of general importance, we were able
to demonstrate that not only protein regulations after
p53-activating stimuli but also the p53 status of the tumor
cell impacts apoptosis sensitivity both during extrinsic and
intrinsic apoptosis induction.
The heterogeneous impact of p53 on cell death induc-
tion has attracted much notice during the recent years
and further contributed to the complex and so far only
rudimentary knowledge of p53 action. Formerly, p53
was thought to act primarily as a transcription factor
and that the activity of p53 in wild-type conformation is
mainly pro-apoptotic while certain mutants reduce the
sensitivity towards apoptotic stimuli. Besides its tran-
scriptional activating function, p53 was also proven for
its repression of the transcription of anti-apoptotic pro-
teins like Bcl-2 [25]. The recognition, that mutant p53 re-
tains at least partial pro-apoptotic activities and that p53 in
its non-mutated form can inhibit cell death induction, fur-
ther contributed to the complexity [7,13,16,17]. Thereby,
p53 activation within the identical cell can result in apop-
tosis promotion or inhibition depending on the stimuli and
the experimental setting [2-4]. The lack of knowledge is
evident, as p53 can also regulate protein expression inde-
pendent from the direct transcriptional activity i.e. by post-
transcriptional regulations and can directly activate the
apoptotic machinery at the mitochondrial level [13,26-31].
We suggest that the impact of baseline p53 expression on
the apoptosis inducing capacity of single agents and drug
combinations should be studied in detail due to the major
impact on extrinsic and intrinsic apoptosis sensitivity
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TRAIL sensitivity in the presence of p53
Figure 3 The heterogenous impact of p53 on extrinsic cell death induction in tumor cell lines. A) Parental RKO cells and derivative cells
with somatic knockout of p53 (left panel) and BJAB (central panel) and SHEP (right panel) cells stably transfected with shRNA against p53 or a
mock sequence were stimulated with TRAIL as in Figure 1A. The impact of baseline p53 expression on extrinsic cell death induction was classified
as augmented cell death whenever the presence of p53 was associated with increased TRAIL sensitivity (left panel), as unchanged whenever p53
did not impact cell death by TRAIL (central panel) and as reduced when the presence of p53 diminished apoptosis induction by TRAIL
(right panel). B) n = 12 different tumor cell lines from Figure 3A and Additional file 1: Figure S3 were classified according to their response to
extrinsic cell death induction in dependence of the p53 status. C) Tumor cell lines from Figure 3B were categorized in the context of the tumor
type, the TRAIL response of the p53 expressing cells and the p53 status of the tumor cells. TRAIL resistance was defined as cell death induction
< 10%. D) The n = 12 cell lines from Figure 3B were analyzed for the relative p53 content as in Additional file 1: Figure S4. Samples were arranged
separated for their TRAIL response in the presence of p53. Apoptosis induction in hematopoietic cells was determined by forwardside scatter
analysis, in solid tumor cells using Nicoletti staining. Calculation of specific apoptosis, presentation of data and Western Blot analysis were
performed as in Figures 1 and 2. Statistical analysis was performed using paired t-test. *p < 0,05, NS = statistically not significant.
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should consider p53 functions independent from the clas-
sical view of protein or cell cycle regulations [8,9,30].
Specific p53 gene mutations displayed a variety of onco-
genic properties mostly referred to as gain-of-function.
These were mainly categorized according to the properties
including tumor formation, augmented tumor cell growth,
transformation, invasiveness, metastasis formation and in-
hibition of DNA repair and differed depending on thespecific p53 mutation [14,15,32]. The data presented here
clearly indicate a further dimension of complexity as wild-
type p53 can act in a pro-apoptotic manner when the in-
trinsic cell death cascade is activated while it can reduce
apoptosis sensitivity via the extrinsic signaling cascade in
the identical tumor cell.
We had described before, that stimulation with TRAIL
can result in four different net effects, namely cell death
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TRAIL sensitivity in the presence of p53
Figure 4 The heterogenous impact of p53 on extrinsic cell death induction in xenografted ALL cells. A) Patient-derived ALL-10S (left
panel), ALL-54 (central panel) and ALL-177 (right panel) cells transfected with siRNA against p53 (sip53) or a control sequence (sicontrol) were
stimulated with TRAIL (100 ng/ml) for 24 hours. Knockdown-efficiency of p53 by RNA interference is presented in Additional file 1: Figure S4.
B) Cells from n = 11 different xenograft samples with wildtype p53 status (from Figure 4A and data not shown) were classified as in Figure 3B.
C) Patient-derived ALL cells from Figure 4B were separated by the type of leukemia, the state of disease and the TRAIL sensitivity in the presence
of p53 as in Figure 3C. D) Patient-derived ALL cells from Figure 4B were analyzed for the relative p53 content as in Figure 3D. Cell death
induction, calculation of specific apoptosis, presentation of data and statistical analysis were performed as in Figure 3. *p < 0,05, paired t-test. NS
= statistically not significant.
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type AP cells and selective induction of proliferation in
type P cells [33]. The heterogeneous responses described
before probably reflect the diversity of each individual
tumor and account for the complexity that has to be
taken into account when the individual tumor cell is
treated at its best. In line, the data presented in this study
suggest that the cell death inducing capacity of TRAIL is
regulated at many different steps and that besides the
proper DISC formation, p53 itself has a major impact on
the TRAIL efficacy. While for the proper DISC assembly,
the presence and balance of the DISC members is crit-
ical, the p53 impact seems to be much more complex asit is not caused by the regulation of classical p53 target
proteins, the cell cycle or spontaneous growth [1,33-35].
In summary, future preclinical and clinical studies in-
vestigating the implementation of the death inducing lig-
and TRAIL in clinical combination therapy protocols
should not only take into account the critical signaling
steps of TRAIL cell death induction but the impact of
p53 status of the individual tumor cell on TRAIL sensi-
tivity. The data presented here clearly indicate, that the
restoration of p53 function is not always beneficial.
Therefore, both strategies, restoration of p53 functional-
ity and inhibition of p53 can be beneficial depending on
the individual tumor. We suggest further evaluation of
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ing within in a similar experimental setting as described
here. The results from the in vitro testing to predict the
impact of p53 on apoptosis induction should be taken to
determine the personalized in vivo treatment and to test
the superiority of this approach in comparison to the
standard protocol.
Conclusions
The data presented add substantially to the knowledge of
p53 functionality. p53 in wild-type status has long been
thought to act as a tumor suppressor. Many studies have
been performed to take advantage of the activation and
restoration of wild-type p53 function which has proven
beneficial in many different experimental settings. During
the recent years, the complexity of p53 function has become
evident. Unfortunately, at least under certain circumstances
the advantage can turn into a disadvantage. The molecular
data presented here prove that not only p53 activation but
the baseline presence of p53 can impact cell death induc-
tion. The detailed analyses of p53 in wild-type conformation
and of frequent p53 mutations disclose the complexity and
the heterogeneous impact on extrinsic and intrinsic apop-
tosis induction. Surprisingly, even wild-type p53 status can
act in an anti-apoptotic manner. The results presented
highlight the need for the gain of knowledge and for the
consideration of p53 function within the particular context
and for the individual tumor to optimize therapy efficacy.
Methods
Materials
TRAIL was prepared as described recently [36]. Alterna-
tively, TRAIL without any modification was obtained
from Pepro Tech (Hamburg, Germany) and rendered
identical results (data not shown). All further reagents
were obtained from Sigma (St. Louis, MO).
For Western Blot, the following antibodies were used:
anti-FADD, anti-FLIP and anti-XIAP from BD Biosciences
(Franklin Lakes, NJ), anti-Bcl-xL, anti-Bid, anti-cIAP-1
and anti-PUMA from Cell Signaling; anti-Bak, anti-Bax,
anti-Bcl-2, anti-cIAP-2, anti-Mcl-1 and anti-p53 from
Santa Cruz (Santa Cruz, CA); anti GAPDH from Thermo
Fisher (Waltham, MA) and anti NOXA from Calbiochem
(San Diego, CA). For flow cytometric determination of
TRAIL surface receptor expression, anti-DR4 and anti-
DR5 were obtained from AXXORA (Lörrach, Germany)
and anti-IgG conjugated to Alx647 from Life Technologies
(Darmstadt, Germany).
Cell lines, xenograft ALL cells and transfection
experiments
HCT116, RKO and SW48 p53 +/+ and p53- / - cells were
obtained from B. Vogelstein (Johns Hopkins University,
Baltimore, MD). All further cell lines were obtained fromDSMZ (Braunschweig, Germany) and maintained as de-
scribed [2-4,37,38]. For leukemic cell line experiments,
cells were seeded at 0,25 × 106/ml, for stimulations with
solid tumor cells at 0,05 × 106/ml and incubated with
TRAIL for 48 hours.
Informed consent was obtained from all patients in writ-
ten form and studies were approved by the ethical com-
mittee of the medical faculty of the Ludwig Maximilians
University Munich (LMU 068-08) and the children’s hos-
pital of the TU Munich (TU 2115/08). Animal work was
approved by the Regierung von Oberbayern (55.2-1-54-
2531-2-07). The xenograft mouse model and engraftment,
amplification, isolation and standardized procedures of
siRNA interference and in vitro stimulation have been de-
scribed in detail recently [3,4,21]. For the knockdown of
p53, siRNA p53 (50- GGGUUAGUUUACAAUCAGC -30)
was obtained from Ambion (Austin, TX) and as control
All Star negative control siRNA from Qiagen (Hilden,
Germany). The p53 status of the xenograft cells was deter-
mined using next-generation sequencing as described be-
fore [39].
Transfection experiments in cell lines where performed
using lipofection or lentiviral transduction as described re-
cently [2,3,38]. pCDH p53 constructs were generated by
the insertion of p53 in wildtype status into the pCDH
plasmid modified as described recently [34] and site spe-
cific mutations were generated by QuikChange II site-
directed mutagenesis PCR kit from Agilent (Santa Clara,
CA). Five different point mutations were generated by
site-directed mutagenesis PCR at codon 143, 175, 248,
249 or 273. Shield-1 (Clontech, Saint-Germain-En-Laye,
France) was used at 0,3 μM. shRNA p53 and correspond-
ing mock sequences, constructs and protocols for trans-
fection were previously described in detail [2,3,38]. DR4
and DR5 cDNAs obtained from imaGENES GmbH
(Berlin, Germany) were cloned into pcDNA3.1 [36].
Apoptosis assays, flow cytometry and Western blot analysis
For leukemia cell lines and xenograft ALL cells, forwardside
scatter analysis was performed and verified using the re-
cently described Annexin V – propidium iodid double
staining [2]. For all adherent cell lines, cell death induction
was determined using Nicoletti staining.
For the determination of TRAIL receptor surface ex-
pression, cells were washed in PBS followed by incubation
with the primary antibody and by subsequent incubation
with a dye-conjugation anti-IgG antibody conjugated to
Alx647. The MFI (mean fluorescence intensity) was deter-
mined on a LSR II (BD Biosciences) using the Cell Quest
Pro software version 3.2.1 (BD Biosciences) for data acqui-
sition and FlowJo software version 8.3. (FlowJo, Ashland,
OR) for data analyses.
Western Blot analysis was performed of total cellular
lysates as described recently for cell lines and patient-
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blot analysis of primary samples by AIDA Image Analyzer
(Raytest; Straubenhardt, Germany) had been described re-
cently [3].Statistical analysis
TRAIL resistance was defined as cell death induction of
<10% by 100 ng/ml TRAIL.
All data are presented as the mean values of at least
three independent experiments ± SEM unless otherwise
stated. To test for significant differences, the paired t-test
was applied to compare two groups; for multivariate ana-
lysis, one way RM ANOVA was used. Statistical signifi-
cance was accepted with p < 0,05.Availability of supporting data
The data sets supporting the results of this article are in-
cluded within the additional file 1.Additional file
Additional file 1: Figure S1. TRAIL sensitivity not affected by TRAIL
death receptor overexpression in SHEP cells. A,B)SHEP cells were
transiently transfected with DR4 and DR5 expression plasmids. The
change in DR4 (left panel) and DR5 (right panel) surface receptor
expression was determined 36 hours after transfection as in Figure 1B
(A) or cells were stimulated with TRAIL (100 ng/ml, B) for another
24 hours. Cell death induction, calculation of specific apoptosis,
presentation of data and statistical analysis were performed as in Figure 1.
*p < 0,05, one way RM ANOVA. NS = statistically not significant.
Figure S2. Different impact of mutant p53 on extrinsic and intrinsic cell
death induction in SHEP cells. A,B)pCDH constructs containing the
different p53 variants were induced in SHEP cells as in Figure 2. SHEP
cells were stimulated with doxorubicin (100 ng/ml, A) or TRAIL
(100 ng/ml, B) for 48 hours. Cell death induction, calculation of specific
apoptosis, presentation of data and statistical analysis were performed
as in Figure 2. *p < 0,05, one way RM ANOVA. NS = statistically not
significant. Figure S3. The heterogenous impact of p53 on extrinsic cell
death induction in tumor cell lines. A-C)n = 8 pairs of cell lines with
baseline p53 expression and downregulated p53 by RNA interference
against p53, somatic knockout of p53 (SW48) or after transfection with
the pCDH p53 wt expression plasmid (H1299) into p53 negative cells
were separated according to their TRAIL response as in Figure 3A. TRAIL
sensitivity in the presence of p53 was classified as augmented (A),
unchanged (B) or reduced (C) efficacy. Stimulation with TRAIL, cell death
induction, calculation of specific apoptosis, Western Blot analysis,
presentation of data and statistical analysis were performed as in Figure 3.
*p < 0,05, paired t-test. NS = statistically not significant. Figure S4. p53
knockdown by RNA interference in xenografted ALL cells. ALL-10S, ALL-
54 and ALL-177 xenograft cells from Figure 4A were transfected with
siRNA against p53. 48 hours later, Western Blot analysis was performed
to prove knockdown efficiency. To enable the quantification of RNA
interference, the p53 expression was investigated standardized to the
expression level of GAPDH. The band density was analyzed using AIDA
Image Analyzer and the relative expression level of p53 was calculated as
(sample expression of p53 / sample expression of GAPDH) for sicontrol and
sip53 transfected cells as described recently [21]. The reduction of p53
expression in sip53 transfected cells was calculated as [(relative p53
expression in sip53 cells / relative p53 expression in sicontrol cells) minus 1].
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